No. 23andMe is considered a direct-to-consumer genetic testing company, and transactions with the company are considered commercial, not medical. Because 23andMe is not a medical company, customers' ...
Upcoming Anticipated Clinical Milestones AMPLIFY-201: Provide updated RFS and OS data in an oral presentation at the 2024 ESMO Immuno-Oncology Congress, taking place from December 11-13, 2024, in ...
Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient ...
The largest ever clinical trial of T cell therapy for solid tumors has ended, heralding a new era for precision T cell therapy.
esmo group (esmo), a leading global full-service systems integrator, developer, and supplier of innovative and advanced automation solutions, is proud to announce the launch of its latest product—the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback